Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 18/20 | 0.52 |
| ▸ | AKT2 | P31751 | 18/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.50 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.49 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.49 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1137816 | 0.92 | AKT1 (0.56) | AKT1AKT2KCNH2 | |
| SCHEMBL1137659 | 0.92 | AKT1 (0.51) | AKT1AKT2KCNH2 | |
| SCHEMBL1137945 | 0.90 | AKT1 (0.57) | AKT1AKT2KCNH2 | |
| SCHEMBL1137820 | 0.90 | AKT1 (0.50) | AKT1AKT2KCNH2 | |
| SCHEMBL1137847 | 0.90 | AKT1 (0.52) | AKT1AKT2KCNH2 | |
| SCHEMBL1137779 | 0.85 | AKT1 (0.49) | AKT1AKT2KCNH2 | |
| SCHEMBL1137849 | 0.85 | AKT1 (0.59) | AKT1AKT2KCNH2 | |
| SCHEMBL1137773 | 0.84 | AKT1 (0.46) | AKT1AKT2KCNH2 | |
| SCHEMBL2271522 | 0.80 | AKT1 (0.58) | AKT1AKT2KCNH2 | |
| SCHEMBL5497263 | 0.80 | AKT1 (0.75) | AKT1AKT2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1737843-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2011-02-23 | — | — | EP | claimed |
| US-7655649-B2 | Cancer; N,N-dimethyl-5-phenyl-6-(4-{[4-(5-pyridin-2-yl-1H-pyrazol-3-yl)piperidin-1-yl]methyl}phenyl) pyridazin-3-amine;; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, enhanced pharmacokinetic properties | MERCK SHARP & DOHME CORP. (US) | 2010-02-02 | — | — | US | claimed |
| EP-1737843-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2009-01-28 | — | — | EP | claimed |
| US-20080280889-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | claimed |
| EP-1737843-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | claimed |
| WO-2005100344-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | claimed |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DEL MAR PHARMACEUTICALS (BC) LTD. (CA) | 2022-09-20 | — | — | US | disclosed |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-20 | — | — | US | disclosed |
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2019-06-13 | — | — | US | disclosed |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS INC (CA) | 2018-03-15 | — | — | US | disclosed |
| WO-2017075052-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DELMAR PHARMACEUTICALS, INC. (CA) | 2017-05-04 | — | — | WO | disclosed |
| US-8003643-B2 | Inhibitors of Akt activity | MERCK SHARP & DOHME CORP. (US) | 2011-08-23 | — | — | US | disclosed |
| EP-1737843-B1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME (US) | 2011-02-23 | — | — | EP | disclosed |
| US-20100075970-A1 | INHIBITORS OF AKT ACTIVITY | MERCK SHARP & DOHME CORP. | 2010-03-25 | — | — | US | disclosed |
| US-7655649-B2 | Cancer; N,N-dimethyl-5-phenyl-6-(4-{[4-(5-pyridin-2-yl-1H-pyrazol-3-yl)piperidin-1-yl]methyl}phenyl) pyridazin-3-amine;; serine/threonine kinase (Akt) suppression; increased cellular potency or solubility, enhanced pharmacokinetic properties | MERCK SHARP & DOHME CORP. (US) | 2010-02-02 | — | — | US | disclosed |
| EP-1737843-A4 | INHIBITORS OF AKT ACTIVITY | MERCK & CO INC (US) | 2009-01-28 | — | — | EP | disclosed |
| US-20080280889-A1 | Inhibitors of Akt Activity | MERCK SHARP & DOHME CORP. | 2008-11-13 | — | — | US | disclosed |
| EP-1737843-A1 | INHIBITORS OF AKT ACTIVITY | Merck & Co., Inc. (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005100344-A1 | INHIBITORS OF AKT ACTIVITY | MERCK & CO., INC. (US) | 2005-10-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175541-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | AKT1 829/4885AKT2 1108/4885KCNH2 4730/4885 |
| US-11446274-B2 | Use of dianhydrogalactitol or derivatives or analogs thereof for treatment of pediatric central nervous system malignancies | DCK, CDC7, DNMT1 | AKT1 829/4885AKT2 1108/4885KCNH2 4730/4885 |
| US-20100075970-A1 | INHIBITORS OF AKT ACTIVITY | PIK3CA, AKT2, AKT1 | AKT1 3/4885AKT2 2/4885KCNH2 4512/4885 |
| US-20180071244-A1 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | AKT1 829/4885AKT2 1108/4885KCNH2 4730/4885 |
| US-20190183843-A9 | USE OF DIANHYDROGALACTITOL OR DERIVATIVES OR ANALOGS THEREOF FOR TREATMENT OF PEDIATRIC CENTRAL NERVOUS SYSTEM MALIGNANCIES | DCK, CDC7, DNMT1 | AKT1 829/4885AKT2 1108/4885KCNH2 4730/4885 |
| US-20080280889-A1 | Inhibitors of Akt Activity | AKT2, PIK3CA, AKT1 | AKT1 3/4885AKT2 1/4885KCNH2 4607/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.